Clinical Trial Update: Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS) [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update evaluating armodafinil for neurocognition and cognitive fatigue in multiple sclerosis; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• NUVIGIL (armodafinil)

Snippet

Sponsor: University of Missouri, Kansas City | Conditions: Multiple Sclerosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2013-10-14